A case of INR elevation with remdesivir and warfarin in a hospitalized patient with COVID-19

Liyan Yao*1,2, William Byas1,2, Matthew Li3, Merjona Saliaj1
1 Internal Medicine, Icahn School of Medicine at Mount Sinai, Jamaica, United States
2 School of Medicine, St. George’s University, True Blue, Grenada

Received: April 5, 2021  Accepted: April 28, 2021  Online Published: May 11, 2021
DOI: 10.5430/crim.v8n1p9  URL: https://doi.org/10.5430/crim.v8n1p9

ABSTRACT

Treatments for COVID-19 infection have varied widely within the past year. Remdesivir is the only direct-acting antiviral approved by the Food and Drug Administration with demonstrated efficacy in the management of patients with COVID-19.[1] Commonly reported adverse effects include hepatotoxicity and gastrointestinal symptoms such as nausea and diarrhea. Less common adverse effects include respiratory toxicity, cardiovascular toxicity and nephrotoxicity.[2] We report a case of international normalized ratio (INR) prolongation in a COVID-19 patient receiving concomitant warfarin and remdesivir therapy.

Key Words: Remdesivir, Warfarin, SARS-CoV-2, COVID-19, Hematology

1. INTRODUCTION

Remdesivir (Veklury) is a broad-spectrum antiviral nucleotide prodrug with potent in vitro activity against a range of RNA viruses including SARS-CoV-2.[1] Remdesivir is currently the only direct-acting antiviral approved by the Food and Drug Administration (FDA) for the treatment of Coronavirus Disease 2019 (COVID-19).[2] In a randomized placebo-controlled trial of hospitalized patients with COVID-19, remdesivir in conjunction with standard of care demonstrated a shorter median time to recovery of 10 days compared to 15 days in the placebo group.[3] However, results of a multinational open-label randomized trial did not demonstrate any reduction in rates of in-hospital mortality or requirement for mechanical ventilation.[4]

Numerous adverse effects of remdesivir have been identified. Commonly reported adverse effects include hepatic enzyme elevations, gastrointestinal symptoms, respiratory failure or acute respiratory distress syndrome, hypotension, atrial fibrillation, and acute kidney injury.[5,6] The impact of remdesivir use on the coagulation profile is not well described. As of February 2021, there is only one case reporting elevation of the international normalized ratio (INR) after remdesivir initiation with concomitant warfarin therapy.[7] We present a case of remdesivir-induced INR elevation with concomitant warfarin therapy in a hospitalized patient with COVID-19 pneumonia.

2. CASE PRESENTATION

A 68-year-old African American male with a past medical history of atrial-fibrillation on warfarin, asthma, mitral valve replacement, hypertension, hypothyroidism, hyperlipidemia, cholecystitis, chronic kidney disease stage 3, presented to the emergency department with complaints of left upper quadrant pain for three days since initial onset. The patient describes the onset of pain as sudden, intermittent, cramping in quality, non-radiating, and exacerbated with movement.
He had a confirmed COVID-19 infection diagnosis six days prior to presentation. The patient is a former smoker and resides in an apartment with a roommate who was also diagnosed with COVID-19 at the same time he was. He admits to mild shortness of breath upon exertion and a productive cough with blood specked, white phlegm. He denies chest pain, nausea, vomiting, diarrhea, palpitations, anosmia or ageusia. His home medications include warfarin 4 mg at bedtime Monday and Thursday and 10 mg at bedtime the remaining days, albuterol 90 mcg/act 2 puffs inhaled every six hours as needed, budesonide-formoterol 80-4.5 mcg/act 2 puffs two times a day, diltiazem 360 mg daily, hydrochlorothiazide 25 mg daily, levothyroxine 150 mcg daily, metoprolol 25 mg daily, and rosuvastatin 20 mg daily. Twelve days prior to admission, the patient’s INR at our institution’s Coumadin Clinic was reported at 2.6.

On initial evaluation, the patient was alert and oriented to person, place, and time. The patient’s cardiovascular exam yielded normal rate, irregular rhythm, with S1 and S2 appreciated without any murmurs, rubs, or gallops. Pulmonary exam yielded benign findings with good bilateral air entry and movement with no wheezing or rales appreciated. Chest radiography was obtained which showed reticular markings consistent with atelectasis or edema. Computed tomography (CT) of the abdomen/pelvis without contrast was also obtained and showed the impression of minimal patchy ground-glass opacities in the left lower lobe. Repeat polymerase chain reaction test on presentation was positive for COVID-19 infection. The patient was subsequently admitted for confirmed COVID-19 pneumonia and was initiated on azithromycin 500 mg daily, ceftriaxone 1,000 mg daily, dexamethasone 6 mg daily, vitamin C 1,000 mg, zinc sulfate 220 mg, and remdesivir 200 mg once followed by 100 mg daily. The patient’s home warfarin therapy for atrial fibrillation was resumed in the evening.

The patient’s baseline INR upon hospital admission was 2.3. Based on the day of the week, the patient received 10 mg of warfarin in the evening of admission day 1. The subsequent INR values throughout the hospital course were significantly elevated: day 2-4.1, day 3-4.6 and day 3 repeat -4.9 as shown in Table 1. The patient’s hepatic function panel and platelet count were within normal limits throughout the entire hospital course. The patient was hemodynamically stable on hospital day 3 and was discharged with outpatient follow-up with the Coumadin Clinic for INR monitoring. On day 3 of outpatient follow up, the patient’s INR was still found to be elevated at 3.6. A therapeutic INR was achieved on day eight of outpatient follow up as shown in Table 2. The patient’s inpatient and outpatient INR trends alongside when remdesivir was started and discontinued can be seen in Figure 1.

### Table 1. Patient’s anticoagulation profile during in-patient hospital course

<table>
<thead>
<tr>
<th>Inpatient Day</th>
<th>PT</th>
<th>INR</th>
<th>Warfarin Dose</th>
<th>Remdesivir</th>
<th>Concomitant Therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Day 1 (Admission)</td>
<td>26.4</td>
<td>2.3</td>
<td>10 mg</td>
<td>200 mg IV loading dose</td>
<td>Azithromycin (500 mg), ceftriaxone (1000mg), dexamethasone (6 mg), vitamin C (1000 mg), and zinc (220 mg)</td>
</tr>
<tr>
<td>Day 2</td>
<td>36.9</td>
<td>3.1</td>
<td>4 mg</td>
<td>100 mg</td>
<td>Same as above</td>
</tr>
<tr>
<td>Day 3 (07:28)</td>
<td>54.5</td>
<td>4.6</td>
<td>Hold</td>
<td>100 mg</td>
<td>Same as above</td>
</tr>
<tr>
<td>Day 3 (11:01)</td>
<td>58.4</td>
<td>4.9</td>
<td>Hold</td>
<td>100 mg</td>
<td>Discharged</td>
</tr>
</tbody>
</table>

**Figure 1.** Patient’s inpatient and outpatient INR trends
Table 2. Patients anticoagulation profile at QHC Coumadin clinic. INR goal 2.5-3.5

<table>
<thead>
<tr>
<th>Outpatient Day</th>
<th>PT</th>
<th>INR</th>
<th>Warfarin Dose</th>
<th>Remdesivir</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Day 1</td>
<td>-</td>
<td>-</td>
<td>Hold</td>
<td>Discontinued</td>
<td>Missed appointment-patient instructed to hold warfarin for two days. Return to clinic in 2 days.</td>
</tr>
<tr>
<td>Day 3</td>
<td>43.0</td>
<td>3.6</td>
<td>6 mg</td>
<td>Discontinued</td>
<td>Continue warfarin 6 mg until next clinic appointment in 5 days. Plan to resume to regular dose if INR continues down trending.</td>
</tr>
<tr>
<td>Day 8</td>
<td>25.8</td>
<td>2.2</td>
<td>10 mg except Monday/Thursday. 4 mg Monday and Thursday</td>
<td>Discontinued</td>
<td>Resume regular regimen. Return to clinic in one week for INR levels.</td>
</tr>
<tr>
<td>Day 15</td>
<td>34.2</td>
<td>2.9</td>
<td>Continue regular regimen</td>
<td>Discontinued</td>
<td>Return to clinic in two weeks for INR levels</td>
</tr>
<tr>
<td>Day 29</td>
<td>33.6</td>
<td>2.9</td>
<td>Continue regular regimen</td>
<td>Discontinued</td>
<td>Return to clinic in three weeks for INR levels</td>
</tr>
<tr>
<td>Day 50</td>
<td>36.3</td>
<td>3.1</td>
<td>Continue regular regimen</td>
<td>Discontinued</td>
<td>Return to clinic in three weeks for INR levels</td>
</tr>
</tbody>
</table>

Figure 2. Enzymatic and transport processes involved in remdesivir pharmacokinetics. Adapted from Leegwater 2020.\[8\] Permission obtained via Copyright Clearance Center, RightsLink

3. DISCUSSION

We report a case of INR elevation after initiation of remdesivir for COVID-19 pneumonia in a patient on stable chronic warfarin therapy prior to admission. The INR remained supratherapeutic after discontinuation of remdesivir and returned to therapeutic levels approximately eight days after discontinuation. The Naranjo Adverse Drug Reaction Probability Scale was to be 4, indicating a possible adverse drug reaction.

The mechanism by which remdesivir increases the INR in patients on warfarin is unclear at this time. One possible
Weakly inhibited by remdesivir. It is plausible that decreased metabolism of warfarin through remdesivir-mediated CYP enzyme inhibition may have contributed to the INR elevation in our patient.

Utilization of corticosteroids in this patient may have also contributed to elevations in the INR. Previous studies have shown that the concomitant use of warfarin and short-term corticosteroids such as dexamethasone or methylprednisolone resulted in INR elevations to supratherapeutic levels. The mechanism of this interaction is not well understood at this time but may be due to altered hepatic metabolism of warfarin by corticosteroids as a result of competitive binding at CYP3A4.

Another possible contributor to INR elevations is the use of anti-infectives such as ceftriaxone. Compared to other commonly used anti-infectives, ceftriaxone use was associated with a statistically significant higher peak INR value in patients managed with chronic warfarin therapy. Although the mechanism of interaction is not well defined, INR elevation is likely secondary to disruption of intestinal flora production of vitamin K.

4. Conclusion

Remdesivir is currently recommended for the management of COVID-19 infection. We report a case of possible remdesivir-induced PT-INR elevation in a patient receiving corticosteroids, anti-infectives, and chronic warfarin therapy. The peak INR was detected on day four of remdesivir therapy and returned to target therapeutic levels on day eight after discontinuation of remdesivir. The INR should be closely monitored and dosages should be adjusted accordingly in patients managed with remdesivir and warfarin therapy. Special consideration should be taken for patients on anticoagulants such as Warfarin to avoid possible life threatening complications. Clinicians should be mindful and consistently monitor patients on both Warfarin and Remdesivir for rising INR levels and adjust dosing appropriately.

Conflicts of Interest disclosure

The authors have declared no conflicts of interest.

References